Infosys and government join hands to tackle risks from Anthropic’s 'Mythos' AI model: Sources

Centre moves closer to launching coal exchange: Explained in 10 points

ATF prices rise 10% after Price Stabilisation Fund takes effect: What it means for passengers

IDBI Disinvestment Update: Govt confident on stake sale, eyes over Rs 80,000 crore monetisation in FY27

Gold imports fall after import duty increase

Gurmeet Chadha-backed Neervana Netzero wins Rajasthan Green Innovation Challenge

Rs 2 crore property bought 5 years ago still at Rs 2 crore? Expert explains real challenge in luxury realty

SBI, PNB, BoB drive strongest PSU bank rally in 2 months; what's behind the surge?

Crafting Bharat–Season 3 Episode 5 features Akshay Mehrotra of Fibe 

470% Dividend Declared: This wire maker announces Rs 47 dividend; check record date

Pharma stocks tumbled as the Nifty Pharma index dropped two percent, with Alkem, Ipca, and Divi’s Labs leading losses. Concerns over Trump tariffs, stretched valuations, and margin calls fueled the sell-off.

Pharma stocks decline as Nifty Pharma index slips 2%; Alkem, Ipca, Divi’s lead losses

Budget 2025 boosts healthcare with Rs 98,311 crore allocation, expanding medical education and cancer care while easing drug costs. Pharma stocks gain momentum amid duty cuts and PLI incentives.

Union Budget 2025: Healthcare sector gets Rs 98,311 crore; pharma stocks in focus

Cipla Q3 Results:&nbsp;Pharmaceutical major Cipla on Tuesday reported a 49 per cent year-on-year (YoY) increase in its consolidated net profit for the December quarter (Q3 FY25) at Rs 1,574.6 crore, from Rs 1,068.5 crore in the same quarter last year (Q2 FY25).

Cipla Q3 Results: Pharmaceutical company's net profit rises 49% to Rs 1,575 crore, revenue up 7%

DSP Mutual Fund (MF), Axis MF, Aditya Birla Sun Life MF, ICICI Prudential MF, Motilal Oswal MF, SBI Life Insurance, and Tata AIA Life Insurance have also bought shares in Cipla.

Promoters Samina and Rumana Hamied exit Cipla; sell 1.72% stake for Rs 2,111 crore

Cipla promoters to offload 1.72% stake via Rs 2,000 crore block deal; floor price set at Rs 1,442, a 6% discount to current market price of Rs 1,532.

Cipla Block Deal News: Cipla promoters offload 1.72% stake via block deals at 6% discount

USFDA's VAI classification boosts Cipla’s outlook for niche drug launches, including Abraxane generic

Cipla shares surge nearly 10% after positive USFDA update on Goa facility

'Diwali Offer' Stocks by Anil Singhvi: These 2 largecap, 1 smallcap scrips can give up to 70% return - Check targets 

Zee Business forecasts indicate a three percent year-on-year revenue increase, with Cipla’s Q2 revenue expected at Rs 6,892 crore, up from Rs 6,678 crore in the same quarter last year

Cipla Q2 earnings preview: Margins under pressure as US, domestic sales outlook remains modest

"It is with a heavy heart that I write to formally announce my resignation from the position of Vice Chairman and Non-Executive Director of the company," Cipla Vice Chairman MK Hamied wrote in a letter addressed to the board of the pharmaceutical company.&nbsp;

Cipla Vice Chairman MK Hamied steps down

Cipla's net profit rose 17.77% in Q1; what should investors do? 

Cipla is likely to report its Q1 numbers later today and the Street expects the company to post good show considering the like market share gains.

Cipla Q1 preview: Pharma major to likely report low double-digit growth in PAT;  margins seen to remain steady

According to an exchange filing, the demand covers assessment years from 2015-16 to 2022-23, following assessment and re-assessment orders issued on July 12.

Cipla receives income tax demand of Rs 773 crore

Indraprastha Gas, Cipla, Prestige Estates Projects & Axis Bank, which stocks will be in focus today? News shares and triggers. Know about Stocks In News.

Indraprastha Gas, Cipla, Prestige Estates Projects & Axis Bank, which stocks will be in focus today?

The drugmaker said its product is indicated for the treatment of patients with acromegaly and gastroenteropancreatic neuroendocrine tumours.

Cipla gets USFDA nod to market Lanreotide injection

The&nbsp;reports suggested that&nbsp;the promoter group of Cipla will divest&nbsp;a nearly 2.53 per cent stake in the company via a block deal worth as much as Rs 2,637 crore at a per share price range of Rs&nbsp;1,289.5-1,357.35.&nbsp;

Cipla Block Deal: 2.52% equity changes hands in multiple block deals; shares climb 5%

Cipla share price:&nbsp;At around 10:12 a.m., shares of Cipla traded 5.6 per cent or Rs 75 higher at Rs 1,4145.75 apiece. The market capitalisation of the company stood at Rs&nbsp;1,14,201.98 crore at around the same time.

Cipla reports a 78.7% jump in profits; what should investors do? 

Cipla Q4 Results:&nbsp;Pharmaceutical company Cipla reported a 78.6 per cent year-on-year jump in consolidated net profit to Rs&nbsp;939 crore for the March quarter, exceeding analysts' expectations.

Cipla Q4 Results: Net profit soars 79%, beats analysts' estimates 

Cipla dividend 2024: According to the company, the dividend amount will be paid to eligible investors within 30 days from the date of the Annual General Meeting.

Cipla dividend 2024: Pharma major announces 650% final dividend - Check record date and other details

The recalled drug is used to help control the symptoms of lung diseases, including asthma, chronic bronchitis and emphysema.

Cipla, Glenmark recall drugs in US due to manufacturing issues

According to ICICI Securities, these stocks can help investors get a return of up to 28 per cent in the next one year.

5 pharma stocks that can offer up to 28% return - Check target price by ICICI Securities

cipla

Cipla shareholders looking to receive the company's final dividend of Rs 13 per share for FY26 needed to own the stock before the ex-dividend date, with the pharma major maintaining its steady dividend payout track record.
 

650% Dividend Alert: Cipla shares to turn ex-dividend on this date; are you eligible for the Rs 13 payout?

Dalal Street just finished yet another eventful week. Zee Business has brought details of seven stocks on brokerages' watchlists. Here's how analysts are viewing these buzzing scrips.

From Bharti Airtel to Dr Reddy's Labs, Stocks in Focus on D-Street | Stock Market | BSE | NSE

Cipla shares surge up to 8 per cent as management signals strong FY27 outlook despite weak Q4 profit; stock recovers 23 per cent from 52-week low on pipeline optimism and US growth bets.
 

Why Cipla shares are surging despite weak Q4 results; here’s what brokerages expect next

Cipla is scheduled to report its financial results for the quarter and the year ended March 31 on Wednesday, May 13. Analysts expect the largecap pharmaceutical company to stage a weak performance for the final three months of FY26. Read on to learn about key expectations in the pharma company's upcoming earnings report.   

Cipla Q4 FY26 Results Preview: Largecap drug maker's PAT likely to slump 40%, margin set to fall by 8%

We're approaching the end of a holiday-shortened trading week, and Zee Business has brought details of seven stocks on brokerages' watchlists. Here's how analysts are viewing these buzzing scrips.

From Zydus to Zomato, Stocks in Focus on D-Street | Stock Market | BSE | NSE

Zee Business

Home

Personal Finance

India

Economy

Tech

Auto

Markets

Jobs

Indian Railways

World

Videos

Photos

Cipla News- Zee Business provides latest news on Cipla, Cipla news Today, Top News on Cipla, update on Cipla Stay updated with business news, breaking news headlines.

Cipla

Pharma stocks decline as Nifty Pharma index slips 2%; Alkem, Ipca, Divi’s lead losses

Union Budget 2025: Healthcare sector gets Rs 98,311 crore; pharma stocks in focus

Cipla Q3 Results: Pharmaceutical company's net profit rises 49% to Rs 1,575 crore, revenue up 7%

Promoters Samina and Rumana Hamied exit Cipla; sell 1.72% stake for Rs 2,111 crore

Cipla Block Deal News: Cipla promoters offload 1.72% stake via block deals at 6% discount

Cipla shares surge nearly 10% after positive USFDA update on Goa facility

RECOMMENDED

Infosys and government join hands to tackle risks from Anthropic’s 'Mythos' AI model: Sources

Centre moves closer to launching coal exchange: Explained in 10 points

ATF prices rise 10% after Price Stabilisation Fund takes effect: What it means for passengers

IDBI Disinvestment Update: Govt confident on stake sale, eyes over Rs 80,000 crore monetisation in FY27

Gold imports fall after import duty increase

Gurmeet Chadha-backed Neervana Netzero wins Rajasthan Green Innovation Challenge

Rs 2 crore property bought 5 years ago still at Rs 2 crore? Expert explains real challenge in luxury realty

SBI, PNB, BoB drive strongest PSU bank rally in 2 months; what's behind the surge?

Crafting Bharat–Season 3 Episode 5 features Akshay Mehrotra of Fibe

470% Dividend Declared: This wire maker announces Rs 47 dividend; check record date

'Diwali Offer' Stocks by Anil Singhvi: These 2 largecap, 1 smallcap scrips can give up to 70% return - Check targets

Cipla Q2 earnings preview: Margins under pressure as US, domestic sales outlook remains modest

Cipla Vice Chairman MK Hamied steps down

Cipla's net profit rose 17.77% in Q1; what should investors do?

Cipla Q1 preview: Pharma major to likely report low double-digit growth in PAT; margins seen to remain steady

Cipla receives income tax demand of Rs 773 crore

Indraprastha Gas, Cipla, Prestige Estates Projects & Axis Bank, which stocks will be in focus today?

Cipla gets USFDA nod to market Lanreotide injection

Cipla Block Deal: 2.52% equity changes hands in multiple block deals; shares climb 5%

Cipla reports a 78.7% jump in profits; what should investors do?

Cipla Q4 Results: Net profit soars 79%, beats analysts' estimates

Cipla dividend 2024: Pharma major announces 650% final dividend - Check record date and other details

Cipla, Glenmark recall drugs in US due to manufacturing issues

5 pharma stocks that can offer up to 28% return - Check target price by ICICI Securities

Top News

Infosys and government join hands to tackle risks from Anthropic’s 'Mythos' AI model: Sources

Centre moves closer to launching coal exchange: Explained in 10 points

ATF prices rise 10% after Price Stabilisation Fund takes effect: What it means for passengers

IDBI Disinvestment Update: Govt confident on stake sale, eyes over Rs 80,000 crore monetisation in FY27

Gold imports fall after import duty increase

Gurmeet Chadha-backed Neervana Netzero wins Rajasthan Green Innovation Challenge